A - Rosenstock 2009 {published data only}
Rosenstock J, Reusch J, Bush M, Yang F, Stewart M.
Potential of albiglutide, a long-acting GLP-1 receptor
agonist, in type 2 diabetes. Diabetes Care 2009;32(10):
1880–6.
E - Bergenstal 2010 {published data only}
Bergenstal RM, Wysham C, MacConell L, Malloy J, Walsh
B, Yan P, et al.Efficacy and safety of exenatide once weekly
versus sitagliptin or pioglitazone as an adjunct to metformin
for treatment of type 2 diabetes (DURATION-2): a
randomised trial. Lancet Aug 2010;376:431–9.
E - Blevins 2011 {published data only}
Blevins T, Pullman J, Malloy J, Yan P, Taylor K, Schulteis
C, et al.DURATION-5: Exenatide once weekly resulted in
greater improvements in glycemic control compared with
exenatide twice daily in patients with type 2 diabetes. The
Journal of Clinical Endocrinology and Metabolism 2011;96
(5):1301–10.
E - Diamant 2010 {published data only}
Diamant M, Van GL, Stranks S, Northrup J, Cao D, Taylor
K, et al.Once weekly exenatide compared with insulin
glargine titrated to target in patients with type 2 diabetes
(DURATION-3): an open-label randomised trial. Lancet
2010;375:2234–43.
E - Drucker 2008 {published data only}
Best JH, Boye KS, Rubin RR, Cao D, Kim TH, Peyrot M.
Improved treatment satisfaction and weight-related quality
of life with exenatide once weekly or twice daily. Diabetic
Medicine 2009;26(7):722–8.
Best JH, Rubin RR, Zhuang D, Velez F, Kim T, Peyrot
M. Higher diabetes treatment satisfaction associated with
improved glucose control for both exenatide once weekly
and twice daily. Diabetes 2008;57:A520.
∗ Drucker DJ, Buse JB, Taylor K, Kendall DM, Trautmann
M, Zhuang D, et al.Exenatide once weekly versus twice
daily for the treatment of type 2 diabetes: a randomised,
open-label, non-inferiority study.[see comment]. Lancet
2008;372(9645):1240–50.
L - Kaku 2010 {published data only}
Kaku K, Rasmussen MF, Clauson P, Seino Y. Improved
glycaemic control with minimal hypoglycaemia and no
weight change with the once-daily human glucagon-like
peptide-1 analogue liraglutide as add-on to sulphonylurea
in Japanese patients with type 2 diabetes. Diabetes Obesity
and Metabolism 2010;12:341–7.
L - LEAD 1 Marre 2009 {published data only}
Marre M, Shaw J, Brändle M, BebakarWMW, Kamaruddin
NA, Strand J, et al.Liraglutide, a once-daily human GLP-1
analogue, added to a sulphonylurea over 26 weeks produces
greater improvements in glycaemic and weight control
compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU). DiabeticMedicine 2009;
26:268–78.
L - LEAD 2 Nauck 2009 {published data only}
Nauck M, Frid A, Hermansen K, Shah NS, Tankova
T, Mitha IH, et al.Efficacy and safety comparison of
liraglutide, glimepiride, and placebo, all in combination
with metformin, in type 2 diabetes: the LEAD (liraglutide
effect and action in diabetes)-2 study. Diabetes Care 2009;
32(1):84–90.
L - LEAD 4 Zinman 2009 {published data only}
Zinman B, Gerich J, Buse JB, Lewin A, Schwartz S, Raskin
P, et al.Efficacy and safety of the human glucagon-like
peptide-1 analog liraglutide in combination with metformin
and thiazolidinedione in patients with type 2 diabetes
(LEAD-4 Met+TZD). Diabetes Care 2009;32(7):1224–30.
L - LEAD 5 Russell-J 2009 {published data only}
Russell-Jones D, Vaag A, Schmitz O, Sethi BK, Lalic N,
Antic S, et al.Liraglutide vs insulin glargine and placebo in
combination with metformin and sulfonylurea therapy in
type 2 diabetes mellitus (LEAD-5 met+SU): a randomised
controlled trial. Diabetologia 2009;52:2046–55.
L - LEAD 6 Buse 2009 {published data only}
Buse J, Sesti G, Schmidt WE, Montanya E, Chang CT,
Xu Y, et al.Switching from twice-daily exenatide to oncedaily
liraglutide improves glycemic control in T2D on oral
agents. American Diabetes Association. 2009:591–P.
∗ Buse JB, Rosenstock J, Sesti G, Schmidt WE, Montanya
E, Brett JH, et al.Liraglutide once a day versus exenatide
twice a day for type 2 diabetes: a 26-week randomised,
parallel-group, multinational, open-label trial (LEAD-
6).[see comment]. Lancet 2009;374(9683):39–47.
L - Pratley 2010 {published data only}
Pratley RE, Nauck M, Bailey T, Montanya E, Cuddihy
R, Filetti S, et al.Liraglutide versus sitagliptin for patients
with type 2 diabetes who did not have adequate glycaemic
control with metformin: a 26-week, randomised, parallelgroup,
open-label trial. Lancet 2010;375:1447–56.
L - Yang 2010 {published data only}
Yang W, Chen L, Ji Q, Liu X, Ma J, Tandon N, et
al.Liraglutide provides similar glycaemic control as
glimepiride (both in combination with metformin) and
reduces body weight and systolic blood pressure in Asian
population with type 2 diabetes from China, South Korea
and India: a 16-week, randomized, double-blind, active
control trial. Diabetes, Obesity and Metabolism Jan 2011;13
(1):81–88.
Lixi - Ratner 2010 {published data only}
Ratner RE, Rosenstock J, Boka G, DRI6012 Study
Investigators. Dose-dependent effects of the once-daily
GLP-1 receptor agonist lixisenatide in patients with
Type 2 diabetes inadequately controlled with metformin:
a randomized, double-blind, placebo-controlled trial.
Diabetic Medicine 2010;27(9):1024–32.
LY2189265 -Umpierrez 2011 {published data only}
Umpierrez GE, Blevins T, Rosenstock J, Cheng C, Anderson
JH, Bastyr EJ 3rd, EGO Study Group. The effects of
LY2189265, a long-acting glucagon-like peptide-1 analog,
in a randomized, placebo-controlled, double-blind study
of overweight/obese patients with type 2 diabetes: the
EGO study. Diabetes, Obesity and Metabolism Jan 2011;13:
418–25.
T - Nauck 2009 {published data only}
Nauck MA, Ratner RE, Kapitza C, Berria R, Boldrin
M, Balena R. Treatment with the human once-weekly
glucagon-like peptide-1 analog taspoglutide in combination
with metformin improves glycemic control and lowers
body weight in patients with type 2 diabetes inadequately
controlled with metformin alone: a double-blind placebocontrolled
study. Diabetes Care 2009;32(7):1237–43.
T- Ratner 2010 {published data only}
Ratner R, Nauck M, Kapitza C, Asnaghi V, Boldrin
M, Balena R. Safety and tolerability of high doses of
taspoglutide, a once-weekly human GLP-1 analogue, in
diabetic patients treated with metformin: a randomized
double-blind placebo-controlled study. Diabetic Medicine
2010;27:556–62.
Abraham 2002
Abraham EJ, Leech CA, Lin JC, Zulewski H, Habener
JF. Insulinotropic hormone glucagon-like peptide-1
differentiation of human pancreatic islet-derived progenitor
cells into insulin-producing cells. Endocrinology 2002;143
(8):3152–61.
ADA 1997
American Diabetes Association. Report on the Expert
Committee on the Diagnosis and Classication of Diabetes
Mellitus. Diabetes Care 1997;20(Suppl 1):S5–20.
ADA 1999
The Expert Committee on the Diagnosis and Classication
of Diabetes Mellitus. Report of the Expert Committee on
the diagnosis and classification of diabetes mellitus. Diabetes
Care 1999;22(Suppl 1):S5–19.
Amori 2007
Amori RE, Lau J, Pittas, AG. Efficacy and safety of incretin
therapy in type 2 diabetes. Journal of the American Medical
Association 2007;298(2):194–206.
Baggio 2004
Baggio LL, Huang Q, Brown TJ, Drucker DJ. A
recombinant human glucagon-like peptide (GLP)-1-
albumin protein (albugon) mimics peptidergic activation of
GLP-1 receptor-dependent pathways coupled with satiety,
gastrointestinal motility, and glucose homeostasis. Diabetes
2004;53(9):2492–500.
Barnett 2009
Barnett AH. New treatments in type 2 diabetes: a focus on
the incretin-based therapies. Clinical Endocrinology 2009;
70:343–53.
Butler 2010
Butler PC, Matveyenko AV, Dry S, Bhushan A, Elashoff R.
Glucagon-like peptide-1 therapy and the exocrine pancreas:
innocent bystander or friendly fire?. Diabetologia 2010;53:
1–5.
Dore 2011
Dore DD, Bloomgren GL,WentenM,Hoffman C, Clifford
CR, Quinn SG, et al.A cohort study of acute pancreatitis in
relation to exenatide use. Diabetes, Obesity and Metabolism
Jun 2011;13(6):559–66.
EMEA 2009
EMEA. Assessment report for Victoza (liraglutide). http://
www.emea.europa.eu/humandocs/PDFs/EPAR/victoza/H-
1026-en6.pdf accessed 10 March 2010.
Farilla 2003
Farilla L, Bulotta A, Hirshberg B, Li CS, Khoury N,
Noushmehr H, et al.Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly
isolated human islets.[see comment]. Endocrinology 2003;
144(12):5149–58.
FDA 2008
FDA. Information for Healthcare
Professionals: Exenatide (marketed as
Byetta). http://www.fda.gov/Drugs/DrugSafety/
PostmarketDrugSafetyInformationforPatientsandProviders/
ucm124713.htm accessed 10 March 2010.
FDA 2009
FDA. Byetta (exenatide) prescribing information. http:
//www.accessdata.fda.gov/drugsatfda˙docs/label/2009/
021773s9s11s18s22s25lbl.pdf accessed 10 March 2010.
FDA 2009 (kidney function)
FDA. Information for Healthcare Professionals:
Reports of Altered Kidney Function in
patients using Exenatide (Marketed as
Byetta). http://www.fda.gov/Drugs/DrugSafety/
PostmarketDrugSafetyInformationforPatientsandProviders/
DrugSafetyInformationforHeathcareProfessionals/
ucm188656.htm accessed 10 March 2010.
FDA 2009 (safety update)
FDA. Byetta Safety Update for Healthcare
Professionals. http://www.fda.gov/Drugs/DrugSafety/
PostmarketDrugSafetyInformationforPatientsandProviders/
DrugSafetyInformationforHeathcareProfessionals/
ucm190406.htm accessed 10 March 2010.
Girman 2010
Girman CJ, Kou TD, Cai B, Alexander CM, O’Neill
EA, Williams-Herman DE, et al.Patients with type 2
diabetes mellitus have higher risk for acute pancreatitis
compared with those without diabetes. Diabetes Obesity and
Metabolism Sep 2010;12(9):766–71.
Higgins 2002
Higgins JPT, Thompson SG. Quantifying heterogeneity in
a meta-analysis. Statistics in Medicine 2002;21:1539–58.
Higgins 2003
Higgins JPT, Thompson SG, Deeks JJ, Altman DG.
Measuring inconsistency in meta-analysis. BMJ 2003;327:
557–60.
Higgins 2011
Higgins JPT, Green S (editors). Cochrane Handbook
for Systematic Reviews of Interventions Version 5.1.0
[updated March 2011]. The Cochrane Collaboration,
2011. Available from www.cochrane-handbook.org.
Journal Watch 2011
Journal Watch. FDA Reminds Clinicians of
Liraglutide’s Risks for Pancreatitis and Cancer. http:/
/firstwatch.jwatch.org/cgi/content/full/2011/614/2?q=
topic˙diabetes accessed 17 June 2011.
Kaku 2010
Kaku K, Rasmussen MF, Clauson P, Seino Y. Improved
glycaemic control with minimal hypoglycaemiaand no
weight change with the once-daily humanglucagon-like
peptide-1 analogue liraglutide as add-onto sulphonylurea in
Japanese patients with type 2 diabetes. Diabetes, Obesity and
Metabolism 2010;12:341-7.
Li 2003
Li Y, Hansotia T, Yusta B, Ris F, Halban PA, Drucker DJ.
Glucagon-like peptide-1 receptor signaling modulates beta
cell apoptosis. The Journal of Biological Chemistry 2003;278
(1):471–8.
Loh and Clement 2007
Loh JA, Clement SC. Efficacy of exenatide therapy over 12
months in a “real world” setting. Diabetes 2007;56:A152.
Moher 2009
Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA
group. Preferred reporting items for systematic reviews and
meta-analysis: the PRISMA statement. British Medical
Journal 2009;339:b2535.
Monami 2009
Monami M, Marchionni N, Mannucci E. Glucagon like
peptide-1 receptor agonists in type 2 diabetes: a metaanalysis
of randomized clinical trials. European Journal of
Endocrinology 2009;160:909–17.
Nathan 2009
Nathan DM, Buse JB, DavidsonMB, Ferrannini E,Holman
RR, Sherwin R, et al.American Diabetes Association,
European Association for Study of Diabetes. Medical
management of hyperglycemia in type 2 diabetes: a
consensus algorithm for the initiation and adjustment of
therapy: a consensus statement of the American Diabetes
Association and the European Association for the Study of
Diabetes. Diabetes Care 2009;32(1):193–03.
Nauck 1993
Nauck MA, Kleine N, Orskov C, Holst JJ, Willms B,
Creutzfeldt W. Normalization of fasting hyperglycaemia by
exogenous glucagon-like peptide 1 (7-36 amide) in type 2
(non-insulin-dependent) diabetic patients. Diabetologia
1993;36(8):741–4.
Nauck 2002
Nauck MA, Heimesaat MM, Behle K, Holst JJ, Nauck
MS, Ritzel R, et a. Effects of glucagon-like peptide 1 on
counterregulatory hormone responses, cognitive functions,
and insulin secretion during hyperinsulinemic, stepped
hypoglycaemic clamp experiments in healthy volunteers.
The Journal of Clinical Endocrinology and Metabolism 2002;
87(3):1239–46.
NICE CG66 2008
National Collaborating Centre for Chronic Conditions.
Type 2 diabetes: national clinical guideline for management
in primary and secondary care. London: Royal College of
Physicians 2008; Vol. http://www.nice.org.uk/nicemedia/
pdf/CG66FullGuideline0509.pdf.
NICE CG87 2009
National Institute for Health and Clinical Excellence. Type
2 diabetes: the management of type 2 diabetes. NICE
clinical guideline 87 2009; Vol. http://www.nice.org.uk/
cg87.
NICE TA203 2010
National Institute for Health and Clinical Excellence.
Liraglutide for the treatment of type 2 diabetes mellitus.
NICE technology appraisal guidance 203. http://
guidance.nice.org.uk/TA203 2010.
Norris 2009
Norris SL, Lee N, Thakurta S, Chan BKS. Exenatide
efficacy and safety: a systematic review. Diabetic Medicine
2009;26:837–46.
Pratley 2008
Pratley RE. Overview of glucagon-like peptide-1 analogs
and dipeptidyl peptidase-4 inhibitors for type 2 diabetes.
Medscape Journal of Medicine 2008;10(7):171.
Shyangdan 2010
Shyangdan DS, Royle PL, Clar C, Sharma P, Waugh
NR. Glucagon-like peptide analogues for type 2 diabetes
mellitus: systematic review and meta-analysis. BMC
Endocrine Disorders 2010;10:20.
Shyangdan 2011
Shyangdan D, Cummins E, Royle P, Waugh N. Liraglutide
for the treatment of type 2 diabetes. Health Technology
Assessment 2011;15(Suppl. 1):75–84.
Turner 1996
Turner RC, Holman RR. The UK Prospective Diabetes
Study. UK Prospective Diabetes Study Group. Annals of
Medicine 1996;28(5):439–44.
UKPDS 16
UKPDS Study Group. UKPDS 16. Overview of 6 years’
therapy of type II diabetes: a progressive disease. UK
Prospective Diabetes Study Group. Diabetes 1995;44:
1249–58.
Waugh 2010
Waugh N, Cummins E, Royle P, Clar C, Marien M, Richter
B, et al.Newer agents for blood glucose control in type
2 diabetes: systematic review and economic evaluation.
Health Technology Assessment July 2010;14(36):1–248.
WHO 1998
Alberti KM, Zimmet PZ. Definition, diagnosis and
classification of diabetes mellitus and its compliactions.
Part I: diagnosis and classification of diabetes mellitus.
Provisional report of a WHO consultation. Diabetic
Medicine 1998;15:539–53.
Xu 1999
Xu G, Stoffers DA, Habener JF, Bonner-Weir S. Exendin-
4 stimulates both beta-cell replication and neogenesis,
resulting in increased beta- cell mass and improved glucose
tolerance in diabetic rats. Diabetes 1999;48(12):2270–6.